Tolterodine Tartrate to Relieve Ureteral Stent Related Overactive Bladder Symptoms

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004459

Enrollment

Unknown

Registered

2014-04-03

Start date

2014-04-05

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

treatment group:Tolterodine Tartrate

control group:no related treatment

Eligibility

Sex/Gender

All

Age

22 Years to 72 Years

Inclusion criteria

Inclusion criteria: The criterion for entry into this study was unilateral placement of double-J stent after ureteral surgery for varieties of reasons, including ureteroscopy,percutaneous nephrolithotomy and ureteroplasty.

Exclusion criteria

Exclusion criteria: The exclusion criteria included BPH-related lower urinary symptoms,a history of chronic prostatitis, interstitial cystitis,chronic cystitis, and chronic medication with anticholinergics.

Design outcomes

Primary

Measure	Time frame
overactive bladder symptoms score;	—

Countries

China

Contacts

Public ContactBIng Li

Union Hospital, Tongji Medical Colleage, Huazhong University of Science and Technology

ahzhanglong@126.com+86 18162528961

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026